Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Rivoceranib for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is testing rivoceranib, a medication, in adults whose ACC cancer has come back or spread. Rivoceranib aims to block signals that help cancer cells grow. Participants will stay on the treatment as long as it is effective and tolerable.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service